Bracco Diagnostics announced that the Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for READI-CAT 2 and READI-CAT 2 SMOOTHIE (barium sulfate) oral suspension for use in computed tomography (CT) of the abdomen to delineate the gastrointestinal (GI) tract in pediatric and adult patients. 

The approval of READI-CAT 2 and READI-CAT 2 SMOOTHIE marks the second regulatory approval of a barium-based contrast agent in the United States. This follows the FDA approval of E-Z-HD for oral suspension in February 2016 indicated for double-contrast radiographic examinations of the esophagus, stomach, and duodenum to visualize the GI tract in patients ≥12 years.

RELATED: First Barium-Based Contrast Agent Gets FDA Approval

Barium sulfate, due to its high molecular density is opaque to x-rays and, acts as a positive contrast agent for radiographic studies. It is biologically inert and, therefore, is not absorbed or metabolized by the body, and is eliminated from the GI tract unchanged.

Continue Reading

Both READI-CAT and READI-CAT 2 SMOOTHIES are available in 450mL bottles. READI-CAT 2 SMOOTHIES for pediatric and adult patients are available as berry, banana, creamy vanilla and mochaccino flavors. 

For more information call (877) 272-2269 or visit